Source: Pediatric Blood & Cancer. Conference titles: Annual Conference of the International Society of Paediatric Oncology (SIOP). Unidade: FMRP
Subjects: NEOPLASIAS CEREBRAIS, CRIANÇAS, FÁRMACOS, APOPTOSE
ABNT
RAMOS, Priscila et al. Evaluation of anti-neoplastic effects of inhibition of NFKB by DHMEQ (dehydroxymethylepoxyquinomicin) in pediatric medulloblastoma cell lines. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 18 ago. 2024. , 2011APA
Ramos, P., Castro-Gamero, A. M., Andrade, A. F., Borges, K. da S., Scrideli, C. A., Umezawa, K., & Tone, L. G. (2011). Evaluation of anti-neoplastic effects of inhibition of NFKB by DHMEQ (dehydroxymethylepoxyquinomicin) in pediatric medulloblastoma cell lines. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Ramos P, Castro-Gamero AM, Andrade AF, Borges K da S, Scrideli CA, Umezawa K, Tone LG. Evaluation of anti-neoplastic effects of inhibition of NFKB by DHMEQ (dehydroxymethylepoxyquinomicin) in pediatric medulloblastoma cell lines. Pediatric Blood & Cancer. 2011 ; 57( 5): 806.[citado 2024 ago. 18 ]Vancouver
Ramos P, Castro-Gamero AM, Andrade AF, Borges K da S, Scrideli CA, Umezawa K, Tone LG. Evaluation of anti-neoplastic effects of inhibition of NFKB by DHMEQ (dehydroxymethylepoxyquinomicin) in pediatric medulloblastoma cell lines. Pediatric Blood & Cancer. 2011 ; 57( 5): 806.[citado 2024 ago. 18 ]